News
ACXP
2.330
+4.48%
0.100
Acurx Pharmaceuticals Inc: Statement of changes in beneficial ownership of securities
Press release · 3d ago
Weekly Report: what happened at ACXP last week (0610-0614)?
Weekly Report · 5d ago
Weekly Report: what happened at ACXP last week (0603-0607)?
Weekly Report · 06/10 09:40
Weekly Report: what happened at ACXP last week (0527-0531)?
Weekly Report · 06/03 09:41
Weekly Report: what happened at ACXP last week (0520-0524)?
Weekly Report · 05/27 09:41
12 Health Care Stocks Moving In Tuesday's After-Market Session
Rezolute stock increased by to $ during Tuesday's after-market session. The company's market cap stands at $ million. Rezolute is one of a number of stocks to move upwards in the after- market session. MyMD Pharmaceuticals (NASDAQ:MYMD) shares increased by $ during the session.
Benzinga · 05/21 20:31
Weekly Report: what happened at ACXP last week (0513-0517)?
Weekly Report · 05/20 09:40
Maxim Group Sticks to Its Buy Rating for Acurx Pharmaceuticals (ACXP)
TipRanks · 05/16 17:05
Acurx Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones · 05/16 11:02
HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $12 Price Target
Benzinga · 05/16 10:44
Buy Rating Affirmed for Acurx Pharmaceuticals Amid Promising CDI Drug Candidate Progress and Solid Financials
TipRanks · 05/16 10:27
ACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q1 2024
Investorplace · 05/15 13:53
Acurx Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Acurx Pharmaceuticals Inc reported a quarterly adjusted loss of 28 cents per share for the quarter ended in March. The company's reported revenue was zero; analysts expected zero. The average analyst rating on the company's shares is "buy" The company reported a loss of $ million.
Reuters · 05/15 13:31
Acurx Reports Outcome Of FDA End-of-Phase 2 Meeting And Phase 3 Readiness For Ibezapolstat For Treatment Of C. difficile Infection
Benzinga · 05/15 13:02
ACURX PHARMACEUTICALS INC -PREPARING TO SUBMIT REQUESTS FOR GUIDANCE TO INITIATE CLINICAL TRIALS IN EUROPEAN UNION, UNITED KINGDOM, JAPAN AND CANADA
Reuters · 05/15 13:00
Acurx Pharmaceuticals Q1 2024 GAAP EPS $(0.28) Misses $(0.24) Estimate
Benzinga · 05/15 11:12
*Acurx Pharmaceuticals Ended 1Q With Cash Totaling $8.9M >ACXP
Dow Jones · 05/15 11:05
*Acurx Pharmaceuticals 1Q Loss/Shr 28c >ACXP
Dow Jones · 05/15 11:04
*Acurx Pharmaceuticals 1Q Loss $4.38M >ACXP
Dow Jones · 05/15 11:04
More
Webull provides a variety of real-time ACXP stock news. You can receive the latest news about Acurx Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACXP
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. Phase II clinical data validate the efficacy of its lead antibiotic candidate, as well as pol IIIC as an appropriate bacterial target.